Satoshi Asano

Minami, 7348553, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

Journal: Biological & pharmaceutical bulletin
Published: June 28, 2026

Neuron-specific overexpression of human vasoactive intestinal peptide receptor 2 in mice causes cognitive dysfunction and abnormal dendritic morphology in the prefrontal cortex.

Neuron-specific overexpression of human vasoactive intestinal peptide receptor 2 in mice causes cognitive dysfunction and abnormal dendritic morphology in the prefrontal cortex.

Journal: Journal of pharmacological sciences
Published: September 15, 2025

Assessing spatial variability in land-use impacts on river water quality: a case study of the yura river watershed, Japan.

Assessing spatial variability in land-use impacts on river water quality: a case study of the yura river watershed, Japan.

Journal: Environmental management
Published: May 15, 2025

A novel drug target VIPR2 to regulate migration and proliferation in breast cancer

A novel drug target VIPR2 to regulate migration and proliferation in breast cancer

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: April 30, 2025

Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells.

Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells.

Journal: British journal of pharmacology
Published: September 24, 2024

Brain region-specific neural activation by low-dose opioid promotes social behavior.

Brain region-specific neural activation by low-dose opioid promotes social behavior.

Journal: JCI insight
Published: April 29, 2024

Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.

Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.

Journal: JACS Au
Published: April 05, 2024

Blockade of vasoactive intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 cells.

Blockade of vasoactive intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 cells.

Journal: Journal of pharmacological sciences
Published: November 01, 2023

Development of the vasoactive intestinal peptide receptor 2 (VIPR2) antagonist peptide for the treatment of schizophrenia

Development of the vasoactive intestinal peptide receptor 2 (VIPR2) antagonist peptide for the treatment of schizophrenia

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: March 29, 2023

A new method for assessing depressive-like behaviors in female mice

A new method for assessing depressive-like behaviors in female mice

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: January 03, 2023

Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway.

Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway.

Journal: Peptides
Published: November 08, 2022

AlphaFold version 2.0 elucidates the binding mechanism between VIPR2 and KS-133, and reveals an S-S bond (Cys25-Cys192) formation of functional significance for VIPR2.

AlphaFold version 2.0 elucidates the binding mechanism between VIPR2 and KS-133, and reveals an S-S bond (Cys25-Cys192) formation of functional significance for VIPR2.

Journal: Biochemical and biophysical research communications
Published: October 11, 2022
Showing 1-12 of 35

Last Updated: 09/26/2026